Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Nobilon licenses CoVaccine

Nobilon licenses CoVaccine

26th September 2007

Nobilon International, part of Organon Laboratories has licensed Protherics’ CoVaccine adjuvant for use in pandemic influenza vaccines and also seasonal influenza vaccines in the elderly.

The licensing agreement has given Nobilon exclusive global rights outside the US to develop, manufacture and market two new influenza vaccines containing CoVaccine.

Protherics, the parent company of Organon, will receive upfront payments from Nobilon and will also receive success related milestone payments as well as royalty payments relating to net sales.

Han van den Bosch, director of research and development at Nobilon, expressed his delight to have secured the licensing agreement.

“The very encouraging results in preclinical experiments using Nobilon?s influenza antigen produced by cell culture and Protherics? CoVaccine adjuvant, justifies further clinical development,” he said.

Over 300 million doses of seasonal influenza vaccine are produced each year globally but many suggest that a considerable shortfall would occur in the event of a pandemic influenza outbreak.

Earlier this week, a study published in the Lancet Journal stated that giving elderly people a vaccine to prevent flu-related death is not as effective as reports have previously suggested.

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips and straight to your inbox.